Bristol Myers posts another win for their Otezla competitor, this time with PhII data in psoriatic arthritis
Less than a week after claiming a Phase III victory over Amgen’s Otezla in psoriasis, Bristol Myers Squibb has more positive data out in psoriatic arthritis.
The Phase II readout for the TYK2 contender deucravacitinib (BMS-986165), which BMS announced Monday, showed the experimental drug met its primary endpoint of reducing symptoms by at least 20 percent after 16 weeks. BMS measured two dosage levels for the once-a-day pill, 6 mg and 12 mg, with both outperforming the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.